Figure 3.
Potent, but not modest, Lp(a)-lowering reduces inflammatory receptor expression, with a concomitant functional improvement. (A) Flow cytometry results of inflammatory markers on circulating monocytes before and after AKCEA-APO(a)-LRx treatment, expressed as delta Median Fluorescence Intensity (MFI). Data are represented as mean ± standard deviation. (B) Percentage trans-endothelial migrated CD14+ monocytes before and after AKCEA-APO(a)-LRx treatment. Data are represented as mean ± standard deviation. (C) Correlation between absolute reduction in Lp(a) and percent reduction in trans-endothelial migration. (D) Flow cytometry results of inflammatory markers on circulating monocytes before and after PCSK9ab treatment, expressed as delta MFI. Data are represented as mean ± standard deviation. (E) Percentage trans-endothelial migrated CD14+ monocytes before and after PCSK9ab treatment. Data are represented as mean ± standard deviation and were analysed by Wilcoxon signed rank test (P-values < 0.05 were considered statistically significant).